Synovial fluid was collected from patients with recent knee injury and from patients with early or late stage osteoarthritis. Chondroitin sulfate-substituted aggrecan fragments present in these fluids, and in normal bovine synovial fluid, were purified by cesium chloride gradient centrifugation, enzymically deglycosylated and fractionated by gel filtration on Superose-12. Each sample contained two major aggrecan core protein populations with apparent molecular masses of 90 kD and 150 kD. For all samples, NH2-terminal analysis of both populations gave a single major sequence beginning ARGSV. This NH2 terminus results from cleavage ofthe human aggrecan core protein at the Glu 373-Ala 374 bond within the interglobular domain between the G1 and G2 domains. Cleavage at this site also occurs during control and interleukin-1 stimulated aggrecan catabolism in bovine cartilage explant cultures (Sandy, J., P. Neame, R. Boynton, and C. Flannery. 1991. J. Biol. Chem.
osteoarthritis. sis, and, finally, a gradual destruction ofthe matrix are characteristic ofthe disease process. This sequence ofevents has been best documented by the use ofanimal models ofposttraumatic OA (1) (2) (3) . Cartilage proteoglycan fragments are released to joint fluid after knee injury and in early stages ofboth posttraumatic and primary OA in the human (4) (5) (6) . An important role for matrix metalloproteinases in both normal turnover of connective tissue matrix and in the tissue destruction seen in, for example, OA has been suggested (7, 8) , and an imbalance between tissue metalloproteinases and inhibitors has been demonstrated in animal model OA cartilage (9) , in joint fluids from patients with recent joint injury, and in OAjoint fluids (10, 11). Further, increased expression of mRNAs for collagenase, stromelysin, and metalloproteinase inhibitor has been shown in synovial cells stimulated with interleukin-1 and in synovial cells from rheumatoid or osteoarthritic joints (12) (13) (14) (15) . However, no definitive evidence has yet been presented which demonstrates that these enzymes are directly involved in cartilage matrix breakdown in OA. A detailed characterization ofmatrix fragments released from joint cartilage after trauma and in OA ofthe human could help identify the degradative mechanisms.
Characterization of aggrecan fragments released from bovine explants treated with interleukin-1 in vitro has demonstrated a major cleavage site within the interglobular domain of the proteoglycan core protein which releases large aggrecan fragments from the tissue (16 
Results
Isolation of aggrecan fragments from synovial fluid. Synovial fluids from seven patients (see Table I for clinical data) were subjected to CsCl gradient centrifugation and the gradient fractions were assayed for glycosaminoglycan and protein. In all samples, > 94% of the glycosaminoglycan and < 2.5% of the total protein was recovered from the gradient in the bottom fraction (D1, density -1.55 g/ml). This indicates that the bulk of the aggrecan fragments present in these synovial fluid samples were of high buoyant density and therefore rich in chondroitin sulfate relative to protein.
A portion of the Dl fractions from patients A and F (Table  I) were analyzed on Sepharose CL-2B in the presence of 5% (wt/wt) hyaluronan and 4% (wt/wt) link protein (not shown). The two profiles were very similar and showed the presence ofa polydisperse population of CS-bearing fragments ( Consistent with these findings, fractionation of synovial fluid Dl aggrecan fragments from patients A through G (Table  I) on Superose-12 showed that in all cases the CS-bearing species were large enough to be excluded from Superose-12 (see Fig. 1 , upper panels, for examples), which has an exclusion limit for dextrans of -300 kD. In addition, fractionation of deglycosylated Dl samples on Superose-12 (see Fig. 1 , lower panels, for examples) indicated that the major aggrecan core protein species in all samples were in the apparent molecular mass range of 90-150 kD.
Characterization ofcore proteins. A detailed analysis ofthe Dl aggrecan fragments from the three patients A, D, and F was carried out (see Fig. 1 , a, b, and c, respectively). Superose- 12 profiles are shown for the Dl samples (Fig. 1, upperpanels) and an equivalent portion ofthe corresponding deglycosylated samples ( Fig. 1, lower panels) . It can be seen that the Dl samples were contaminated to a varying degree with nonaggrecan protein, shown as 214 nm absorbance, which eluted in the included fractions with an apparent size below 66 kD. This material was presumably "trapped" with the Dl aggrecan during ultracentrifugation, possibly as a result of a high concentration of hyaluronan and protein in these samples. The identity of these proteins was not further investigated. After deglycosylation, the 214 nm absorbance profiles for each sample (Fig. 1, lower panels) showed two major peaks between fractions 4 and 13 (labelled as I and II). The 214-nm absorbing species eluted between fractions 14 and 22 were apparently not generated by the deglycosylation step but were present in the starting material (note change in absorbance scale between upper and lower panels). The high absorbance at around fraction 26 corresponds to the column Vt and represents components and products of the deglycosylation procedure.
The proteins eluted in pools I and II (Fig. 1 , lower panels) were both derived from the high molecular weight CS-bearing aggrecan fragments shown in the upper panels (fractions 4-10). Thus, when other portions of DI samples from patients A, D, and F were purified on Superose-12, and fractions 4-10 were pooled for deglycosylation, the 214-nm profile of these core samples on Superose-12 again showed the characteristic double peak in fractions 4-11. The Dl preparation from normal bovine synovial fluid showed essentially the same Superose-12 profiles as the human material, for both the untreated and the deglycosylated samples (profiles not shown).
NH2-terminal analysis ofaggrecan coreproteinsfrom synovialfluids. The aggrecan core preparations from Superose-12 chromatography (pools I and II) of both human and bovine synovial fluid samples were taken for NH2-terminal analysis and the results, with approximate picomole yields, are shown in Table II. For all synovial fluids analyzed, and for both pool I and pool II core protein species, the major sequence obtained (see for example, patient A Superose pool I, sequence ARGS-VILXVKP) clearly corresponded to the human aggrecan sequence beginning ARGSVILTVKP, which initiates at Ala 374 within the interglobular domain (from the cDNA, ref. 17). Interestingly, the eighth residue could not be detected in any sample and since this is a threonine in the cDNA-derived sequence, it seems likely that this residue is modified, probably by O-substituted carbohydrate. The finding of the same NH2 terminus on pool I and pool II core species suggests that their separation 
Discussion
Large aggrecan fragments have previously been shown to be present in joint fluids from patients with inflammatory joint disease or OA (21) . We now extend these findings and show that posttraumatic and osteoarthritic human synovial fluid contains at least two populations of aggrecan fragments, both of which are relatively large and both of which carry the NH2-terminal sequence ARGSVILXVK, situated within the interglobular domain. A diagrammatic representation of two possible structures is given in Fig. 2 . It is clear that this NH2 terminus (Ala 374) was not generated by proteolysis during deglycosylation with chondroitinase and keratanase, nor at subsequent stages in the isolation ofcore proteins; thus in control studies with deglycosylated calf articular AlDl aggrecan the only detectable NH2-terminal sequence obtained, VEVS, corresponded to that expected for the intact molecule ( 16) . In addition, the NH2-terminal sequence FFGVGGEEDIXVQ (initiating at Phe 342) was obtained after deglycosylation of stromelysin-generated CS-bearing human aggrecan fragments, with no evidence for an NH2-terminal sequence beginning at Ala 374 (22) . Such species (Fig. 2) would appear to represent the bulk of the CS-bearing fragments present in osteoarthritic human synovial fluid for the following reasons. Firstly, greater than 94% of the fragments recovered from the CsCl gradient were recovered in the Dl fraction. Secondly, all of the fragments in such Dl fractions were present in the void volume on Superose-12 fractionation and deglycosylation of such samples generated only two populations of aggrecan core protein (termed pools I and II). Thirdly, the only detectable sequence in both pool I and pool II samples was ARGSVILXVK and the molar yield ofthis sequence was generally about 25% of the starting protein used in preparation of the samples (assuming a molecular mass of 150 kD for these core proteins). This appears to be a reasonable yield, since two chromatographic steps, with attendant losses, were used in sample preparation for sequencing and the yield in Edman degradation is often only 40-80% of expected. It should be noted, however, that these analyses are confined to CS-bearing fragments ofaggrecan and do not address the structure or abundance ofnonglycosylated fragments such as the G 1 domain shown to be present in human synovial fluids by Witter and co-workers (21) .
The results also show that essentially the same products are released into synovial fluid from normal mature bovine articular cartilage in vivo. In addition, our earlier studies (16) showed that the same NH2-terminal sequence was present on aggrecan fragments released from bovine cartilage in explant cultures both with and without IL-I treatment. Similar studies on aggrecan fragments in the synovial fluid from rabbit joints injected with IL-I have also shown the same major NH2-terminal sequence (McDonnell, J., V. Moore, R. Boynton, C. Flannery, P. Neame, and J. Sandy, unpublished observation).
When taken together, these studies indicate that the protease responsible for cleavage of the Glu 373-Ala 374 bond in the interglobular domain ofaggrecan is widely distributed, and would appear to be part ofa general mechanism for the catabolism of aggrecan in both normal turnover and in pathological situations. This implies that this enzyme is normally expressed by chondrocytes and that overexpression of this activity may be a key event in the pathogenesis of disease states involving accelerated cartilage degradation, such as osteoarthritis.
The finding of this predominant NH2-terminal sequence on aggrecan fragments in all of these situations does not imply that the enzyme which cleaves the Glu 373-Ala 374 bond is the only, or indeed primary enzyme involved in aggrecan catabolism. The results do suggest, however, that this enzyme acts on the majority of catabolized molecules and that it catalyzes the most COOH-terminal cleavage within the interglobular domain. It is thus possible that this enzyme acts secondarily to other proteases which cleave the interglobular domain nearer to the NH2 terminus.
In this regard it may be relevant that stromelysin-1 cleaves the interglobular domain of both human (22) and porcine aggrecan (23) at the Asn 34 1-Phe 342 bond. Further, a proportion of the G1 domain which accumulates in human articular cartilage has Asn 341 as a COOH terminus, indicative of stromelysin-1 action in situ; stromelysin-1 does not, however, appear to catalyze the cleavage ofthe Glu 373-Ala 374 bond (22) .
The protease which cleaves the Glu 373-Ala 374 bond of aggrecan remains to be identified. It (24). Alternatively, it might be a member of the cathepsin group of lysosomal cysteine proteinases (25) . There is direct evidence that in human cartilage in vivo, a proportion of the link protein has been cleaved by cathepsin B which is presumably derived from the chondrocytes (26) . Whatever the nature of this protease, it is almost certainly involved in generation of the short half-life pool ofaggrecan seen in cartilage both in vivo and in vitro (18, 27) . This would indicate that its activity might be particularly high in the pericellular matrix ofcartilage where it would have access to newly secreted aggrecan, thereby implying that this enzyme plays a central role in the control ofaggrecan deposition in cartilage matrix in both normal and diseased states.
The finding that products of this enzyme are present in the synovial fluid of patient A (3 days after anterior cruciate ligament rupture), patient D (15 years after medial meniscectomy), and patient F (10 years of primary OA with extensive cartilage loss), suggests that expression of this activity may be both an early and persistent feature of the chondrocyte response to the joint changes associated with both primary and posttraumatic OA. Identification of the enzyme could allow a rational approach towards the development of a therapy with the aim of retarding or inhibiting cartilage matrix destruction in osteoarthritis.
